Septic Shock
821
95
107
394
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
49 trials with published results (6%)
Research Maturity
394 completed trials (48% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.6%
54 terminated out of 821 trials
87.9%
+1.4% vs benchmark
18%
148 trials in Phase 3/4
12%
49 of 394 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 394 completed trials
Clinical Trials (821)
Immune Dysregulation During Sepsis: A Natural History Cohort
Disseminated Intravascular Coagulation (DIC) Score and Organ Dysfunction in Septic Shock Patients
Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock
Alterations of the Renin-angiotensin-aldosterone System in sEptic Shock
Effect of Targeting Upper Normal Serum Magnesium Levels on Norepinephrine Requirements in Septic Shock Patients
Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation
Effects of Hemoadsorption on Vascular Integrity in Septic Shock
Comparison of Manual PAOP and Automatic PAOP (Smart Wedge)
Albumin and Crystalloid Administration in Septic Shock
ARTICE® Real Data Collection & Observational Trial, Phase 4 Study
Splanchnic Perfusion Monitoring in Septic Shock Using Doppler Ultrasound
Septic Shock-induced Immunosuppression
Continuous Infusion Versus Intermittent Bolus Hydrocortisone in Septic Shock
Association Between Muscle L3 CT Scan Muscle Derived Parameters of Muscle Function Upon Intensive Care Unit Admission and 3 Months Mortality After ICU Discharge for Patients Admitted for Septic Shock. The SIMS Study
Characterizing Perfusion and Congestion Responses to Fluid Loading in Critically Ill Septic Patients
BioMArkeRs of INflammation, Infection, and Immunity in the Critical Area (MARINA): the Use of Inflammatory and Immunity Biomarkers as Early Predictors of Clinical Severity, Organ Damage, Response to Treatment, and Infectious Complications in Patients Admitted to the Critical Care Area.
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation
Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock
TIMP2*IGFBP7 and Transient AKI